Key takeaway: Alembic Pharmaceuticals Limited's investor presentation for the quarter ended June 30, 2026, reported a revenue of INR 21.50 billion, reflecting a 26% year-over-year increase. The India Branded Business achieved a 7% growth with revenues of INR 6.42 billion, while the US Formulation segment saw a significant 49% growth, driven by new product launches. The Ex-US Formulation and API segments also reported growths of 17% and 33%, respectively. EBITDA before R&D was INR 5.23 billion, with an EBITDA margin of approximately 24%. The presentation highlighted a net profit of INR 1.73 billion, representing a 12% increase year-over-year. Management emphasized ongoing investments in R&D, with R&D expenses constituting 9% of revenue. The company also outlined its sustainability goals, including achieving net-zero emissions by 2050 and water neutrality by 2027.

Key takeaway: Alembic Pharmaceuticals Limited held its Q4 FY '26 earnings conference call on May 15, 2026, where management provided insights into the company's performance and strategic direction. The external environment was described as dynamic, with pricing pressure and supply chain volatility impacting results. The India business achieved 4% year-on-year growth, driven by price increases and new product launches, while the international business, particularly in the U.S., showed positive growth. Management reported a 10% year-on-year revenue increase for FY '26, with EBITDA margins improving to 25%. For FY '27, management set a goal of low double-digit top-line growth, emphasizing margin protection and operational efficiency. R&D investments were projected to be between INR750 crores and INR800 crores, focusing on high-value opportunities. The call concluded with management expressing confidence in the company's strategic positioning and growth potential.

Key takeaway: Alembic Pharmaceuticals Limited's investor presentation for the quarter and financial year ended March 31, 2026, reported a 4% year-over-year growth in total revenue, reaching INR 18.48 billion. The India Branded Business achieved a 4% increase in revenue, while the US Formulation segment saw an 11% rise, attributed to key product launches. However, the Ex-US Formulation segment experienced a 2% decline. The presentation highlighted a 39% increase in reported profit after tax, amounting to INR 2.03 billion, with a net profit margin of 11%. R&D expenses rose by 39%, reflecting investments in peptide development. The company set a goal of achieving net-zero emissions by 2050 and emphasized its commitment to sustainability through various initiatives. The document also detailed the company's operational metrics, including ANDA filings and market share rankings in the Indian pharmaceutical market.

Key takeaway: Alembic Pharmaceuticals Limited reported an 11% year-over-year revenue growth for Q3 FY '26, reaching INR 1,876 crores, driven by volume expansion and new product launches, despite facing pricing pressures in U.S. generics and APIs. Gross margin decreased to 72% from 74% due to product mix changes and pricing challenges, but management expressed comfort with the margin level. EBITDA before R&D expenses grew by 20% year-on-year to INR 464 crores, reflecting improved operating leverage. R&D expenses rose by 33% to INR 165 crores, aligning with the full-year guidance of INR 600-650 crores. The company noted a 21% increase in profit after tax before exceptional items, while acknowledging a one-time provision related to the New Labour Code. Management highlighted growth in the India branded business and a strategic focus on profitability and operational excellence, with plans for new product launches in the U.S. market.

Key takeaway: Alembic Pharmaceuticals Limited's investor presentation for the quarter and nine months ended December 31, 2025, reported a 6% year-over-year growth in the India branded business, achieving quarterly revenues of INR 6.52 billion. The US generics segment also saw a 6% increase, driven by product launches and market share gains. The ex-US generics business achieved a record revenue with a 36% year-over-year growth. The API segment reported stable growth of 2%. Key financial highlights included an EBITDA of INR 3.08 billion and a net profit before tax of INR 2.04 billion, reflecting a 33% year-over-year increase. The presentation emphasized ongoing investments in R&D, with R&D expenses constituting 9% of revenue. Additionally, Alembic set sustainability goals, including achieving net zero emissions by 2050 and water neutrality by 2027.

Key takeaway: Alembic Pharmaceuticals Limited presented its unaudited financial results for the quarter and nine months ended December 31, 2025. The presentation highlighted a 17% year-over-year growth in total international generics sales for Q3 FY26, with notable contributions from the USA, Canada, and Australia. The USA direct sales grew by 7%, driven by products like Sacu+Valsartan and Metoprolol. However, some products experienced a decline, such as Formoterol and Timolol Ophthalmic. Year-to-date figures showed a 20% increase in total sales compared to the previous year. The company also reported on its product launches and ANDA filings, indicating ongoing efforts to expand its portfolio. Management noted the performance across various therapeutic areas, with gynecology and cardiology showing significant growth. The presentation concluded with a summary of the company's strategic initiatives and market positioning.